Genmab — November 2016
-
Danske Equities med deres morgenkommentar efter CMD: We attended the Genmab CMD in New York, where Genmab took a deeper dive into the promising proprietary pipeline and showed the frame-work on how it intends to build the business from the expected Darzalex royalty income. We keep our Buy recommendation and 12-month target price of DKK1,470 per share.
-
Elsker at han viser en graf med 30% stigning i år og siger det ikke ligefrem er gået særlig godt

-
Det er der vel ingen som havde forventet?
-
Pipelinen kan man ikke opjusterer på. Det er alt for tidligt.
-
dårlig ide i går på den korte bane at købe op for hver 10 kr den faldt. B
yder nu 1150 -
Det var ikke formålet.
-
Formålet var at fortælle om strategi og målsætning.
-
Planen for fremtiden.
-
Selskabet kan jo ikke komme med kursdrivende nyt på et investormøde. Den slags skal meldes over børsen.
-

-
Der går nok længe før vi ser 125
0 igen i hvert fald
-
1250
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind